Jerome de Seze Selected Research

Immunoglobulin G (IgG)

1/2021	Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.
1/2021	Multiplex assays for the identification of serological signatures of SARS-CoV-2 infection: an antibody-based diagnostic and machine learning study.
4/2019	Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD).
9/2017	Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders.
11/2013	Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.
10/2012	Review of Animal Models of Neuromyelitis Optica.
9/2011	Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders.
1/2008	Neuromyelitis optica and non organ-specific autoimmunity.
10/2006	Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jerome de Seze Research Topics

Disease

9	Neuromyelitis Optica (Devic's Disease) 01/2020 - 01/2008
8	Multiple Sclerosis 01/2022 - 10/2006
2	COVID-19 01/2021 - 01/2021
2	Transverse Myelitis (Necrotizing Myelitis) 09/2011 - 01/2008
2	Optic Neuritis (Retrobulbar Neuritis) 09/2011 - 01/2008
1	Reinfection 01/2021
1	Infections 01/2021
1	Relapsing-Remitting Multiple Sclerosis 04/2019
1	Exanthema (Rash) 04/2019
1	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2019
1	Diffuse Brain Injuries (Diffuse Brain Injury) 07/2015
1	Dementia (Dementias) 01/2014
1	Neuroinflammatory Diseases 10/2012
1	Inflammation (Inflammations) 10/2012
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 09/2011
1	Nervous System Diseases (Neurological Disorders) 09/2011
1	Rheumatic Diseases (Rheumatism) 09/2011
1	Vasculitis (Vasculitides) 09/2011
1	Cognitive Dysfunction 08/2010
1	Atrophy 11/2009
1	Myelitis 01/2008
1	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 10/2006
1	Spinal Cord Diseases 04/2006

Drug/Important Bio-Agent (IBA)

9	Immunoglobulin G (IgG)IBA 01/2021 - 10/2006
4	AntibodiesIBA 01/2021 - 01/2008
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2010
3	AutoantibodiesIBA 11/2013 - 01/2008
2	Monoclonal AntibodiesIBA 01/2021 - 04/2019
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 10/2006
1	ocrelizumabIBA 01/2022
1	Oligoclonal BandsIBA 10/2021
1	diroximel fumarateIBA 01/2021
1	AntigensIBA 01/2021
1	Fingolimod Hydrochloride (FTY720)FDA Link 01/2021
1	Biotin (Vitamin H)FDA Link 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	FumaratesIBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2020
1	teriflunomideIBA 01/2020
1	ofatumumab FDA Link 01/2020
1	Alemtuzumab (Campath)FDA Link 04/2019
1	6-bromo-2-naphthyl sulfate (BNS)IBA 01/2019
1	Myelin-Oligodendrocyte GlycoproteinIBA 01/2019
1	Mycophenolic Acid (Cellcept)FDA LinkGeneric 09/2017
1	Protons (Proton)IBA 07/2015
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2014
1	Aquaporin 4IBA 11/2013
1	anti-aquaporin 4 autoantibodyIBA 09/2011
1	Biological ProductsIBA 08/2010
1	Retinaldehyde (Retinal)IBA 11/2009
1	Surface Antigens (Surface Antigen)IBA 09/2009
1	Antinuclear AntibodiesIBA 01/2008
1	myelin proteolipid protein (139-151)IBA 10/2006
1	Peptides (Polypeptides)IBA 10/2006
1	Adrenal Cortex Hormones (Corticosteroids)IBA 04/2006
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/2006

Therapy/Procedure

2	Therapeutics 09/2017 - 08/2013
1	Aftercare (After-Treatment) 01/2014